Yang Zhan

Yang Zhan

Auto-generated profile, based on publicly available information

Yang Zhan

Department of Medicine McGill University Montreal Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
MCMohammed A. Chamsi-Pasha
Mohammed A. Chamsi-Pasha
YZYang Zhan
Yang Zhan
DDDany Debs
Dany Debs
DSDipan J. Shah
Dipan J. Shah

1 March 2019 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
OKOmar Khalique
Omar Khalique
JCJoão L. Cavalcante
João L. Cavalcante
DSDipan Shah
Dipan Shah
AGAndrada C. Guta
Andrada C. Guta
YZYang Zhan
Yang Zhan
DMDenisa Muraru
Denisa Muraru

7 January 2019 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
PDF file
MKMohammad A. Khan
Mohammad A. Khan
EYEric Y. Yang
Eric Y. Yang
YZYang Zhan
Yang Zhan
RJRobert M. Judd
Robert M. Judd
WCWenyaw Chan
Wenyaw Chan
DSDipan J. Shah
Dipan J. Shah
Routine cine cardiovascular magnetic resonance (CMR) allows for the measurement of left atrial (LA) volumes. Normal reference values for LA volumes have been published based on a group of European individuals without known cardiovascular disease (CVD) but not on one of similar United States (US) based volunteers. Furthermore, the association between grades of LA dilatation by CMR and outcomes has not been established. We aimed to assess the relationship between grades of LA dilatation measured on CMR based on US volunteers without known CVD and all-cause mortality in a large, multicenter cohort of patients referred for a clinically indicated CMR scan. We identified 85 healthy US subjects to determine normal reference LA volumes using the biplane area-length method and indexed for body surface area (LAVi). Clinical CMR reports of patients with LA volume measures (n = 11,613) were obtained. Data analysis was performed on a cloud-based system for consecutive CMR exams performed at three geographically distinct US medical centers from August 2008 through August 2017. We identified 10,890 eligible cases. We categorized patients into 4 groups based on LAVi partitions derived from US normal reference values: Normal (21–52 ml/m2), Mild (52–62 ml/m2), Moderate (63–73 ml/m2) and Severe (> 73 ml/m2). Mortality data were ascertained for the patient group using electronic health records and social security death index. Cox proportional hazard risk models were used to derive hazard ratios for measuring association of LA enlargement and all-cause mortality. The distribution of LAVi from healthy subjects without known CVD was 36.3 ± 7.8 mL/m2. In clinical patients, enlarged LA was associated with older age, atrial fibrillation, hypertension, heart failure, inpatient status and biventricular dilatation. The median follow-up duration was 48.9 (IQR 32.1–71.2) months. On univariate analyses, mild [Hazard Ratio (HR) 1.35 (95% Confidence Interval [CI] 1.11 to 1.65], moderate [HR 1.51 (95% CI 1.22 to 1.88)] and severe LA enlargement [HR 2.14 (95% CI 1.81 to 2.53)] were significant predictors of death. After adjustment for significant covariates, moderate [HR 1.45 (95% CI 1.1 to 1.89)] and severe LA enlargement [HR 1.64 (95% CI 1.29 to 2.08)] remained independent predictors of death. LAVi determined on routine cine-CMR is independently associated with all-cause mortality in patients undergoing a clinically indicated CMR.

1 March 2018 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
YZYang Zhan
Yang Zhan
JJJacqueline Joza
Jacqueline Joza
MRMohamed Al Rawahi
Mohamed Al Rawahi
RBRodrigo S. Barbosa
Rodrigo S. Barbosa
MSMichelle Samuel
Michelle Samuel
VEVidal Essebag
Vidal Essebag

15 September 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
MAMehdi Afshar
Mehdi Afshar
JRJian Rong
Jian Rong
YZYang Zhan
Yang Zhan
HCHao Yu Chen
Hao Yu Chen
JEJames C. Engert
James C. Engert
GTGeorge Thanassoulis
George Thanassoulis
Background: Elevated lipoprotein(a) is a well‐established risk factor for atherosclerotic vascular disease but is not measured in routine clinical care. Screening of high lipoprotein(a) in individuals with moderate elevations of low‐density lipoprotein cholesterol (LDL‐C) may identify individuals at high risk of cardiovascular disease. Methods and Results: We examined 2606 Framingham Offspring participants (median age, 54 years; 45% men) prospectively with a median follow‐up of 15 years (n=392 incident cardiovascular events). Individuals with higher (≥100 nmol/L) versus lower lipoprotein(a) were divided into groups based on LDL‐C <135 mg/dL versus ≥135 mg/dL. In Cox models, after adjustment for known risk factors, high lipoprotein(a) (≥100 nmol/L) and LDL‐C ≥135 mg/dL were each significant predictors of cardiovascular disease (LDL‐C ≥135 mg/dL: hazard ratio [HR], 1.34; 95% CI, 1.09–1.64; P =0.006; high lipoprotein (a): HR, 1.31; 95% CI, 1.03–1.66; P =0.026). Across the groups of high/low lipoprotein (a) and LDL‐C ≥135 mg/dL or <135 mg/dL, the absolute cardiovascular disease risks at 15 years were 22.6% (high lipoprotein(a)/LDL‐C ≥135 mg/dL, n=248), 17.3% (low lipoprotein(a)/LDL‐C ≥135 mg/dL, n=758), 12.7% (high lipoprotein(a)/LDL‐C <135 mg/dL, n=275) and 11.5% (low lipoprotein(a)/LDL‐C <135 mg/dL, n=1328, reference group). Among individuals with LDL‐C ≥135 mg/dL, those with high lipoprotein(a) had a 43% higher risk (HR, 1.43; 95% CI, 1.05–1.97; P =0.02). Presence of high lipoprotein(a) with moderate LDL‐C levels (135–159 mg/dL) yielded absolute risks equivalent to those with LDL‐C ≥160 mg/dL (23.5%, 95% CI, 17.4%–31.3%; and 20.7%, 95% CI, 16.8%–25.3%, respectively). Conclusions: Concomitant elevation of LDL‐C ≥135 mg/dL and lipoprotein(a) ≥100 nmol/L is associated with a high absolute risk of incident cardiovascular disease. lipoprotein(a) measurement in individuals with moderate elevations in LDL‐C, who do not otherwise meet criteria for statins, may identify individuals at high cardiovascular risk.

1 August 2019 in The American Journal of Cardiology
Verified
Journal Article
Closed access
YZYang Zhan
Yang Zhan
DDDany Debs
Dany Debs
MKMohammad A. Khan
Mohammad A. Khan
DNDuc Nguyen
Duc Nguyen
EGEdward A. Graviss
Edward A. Graviss
DSDipan J. Shah
Dipan J. Shah